Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports.
Mosaic ImmunoEngineering Price Performance
Shares of CPMV stock opened at $0.69 on Friday. The stock’s fifty day simple moving average is $0.66 and its 200 day simple moving average is $0.58. Mosaic ImmunoEngineering has a twelve month low of $0.25 and a twelve month high of $1.05. The firm has a market capitalization of $5.03 million, a P/E ratio of -7.72 and a beta of -0.68.
About Mosaic ImmunoEngineering
Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.
Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.
Featured Stories
- Five stocks we like better than Mosaic ImmunoEngineering
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
- Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half
- Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
- Intuit’s Great SaaS Reset: Fired By AI
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.
